Multislice computed tomography assessment of everolimus-eluting Absorb bioresorbable scaffolds in comparison with metallic drug-eluting stents from the ABSORB Japan randomised trial

EuroIntervention 2018;14:e1020-e1028 published online November 2017 published online e-edition October 2018. DOI: 10.4244/EIJ-D-17-00716

Kengo Tanabe
Kengo Tanabe1*, MD; Jeffrey J. Popma2, MD; Ken Kozuma3, MD; Shigeru Saito4, MD; Toshiya Muramatsu5, MD; Sunao Nakamura6, MD; Atsuo Namiki7, MD; Yoshihiro Morino8, MD; Nobuhisa Hagiwara9, MD; Masaaki Uematsu10, MD; Tomohiro Kawasaki11, MD; Kenshi Fujii12, MD; Patrick W. Serruys13, MD; Yoshinobu Onuma13, MD; Shihwa Ying14, MS; Hajime Kusano14, PhD; Gregg W. Stone15, MD; Takeshi Kimura16, MD; on behalf of the ABSORB Japan Investigators
1. Mitsui Memorial Hospital, Tokyo, Japan; 2. Beth Israel Deaconess Medical Center, Boston, MA, USA; 3. Teikyo University Hospital, Tokyo, Japan; 4. Shonan Kamakura General Hospital, Kanagawa, Japan; 5. Tokyo General Hospital, Tokyo, Japan; 6. Shin-Tokyo

Aims: Blooming artefacts limit accurate coronary assessment by multislice computed tomography (MSCT) in metallic stents. We sought to investigate whether bioresorbable vascular scaffolds

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

bioresorbable scaffoldsclinical researchmsct
Stents and scaffolds
Read next article
Comparison between two biodegradable polymer-based sirolimus-eluting stents with differing drug elution and polymer absorption kinetics: two-year clinical outcomes of the PANDA III trial

Latest news